{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:00:08Z","timestamp":1788814808013,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Urovant Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s12325-021-01902-8","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T20:02:49Z","timestamp":1631995369000},"page":"5452-5464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-506X","authenticated-orcid":false,"given":"Michael J.","family":"Kennelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Girman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Shortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Paul N.","family":"Mudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"issue":"5","key":"1902_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","volume":"77","author":"KS Coyne","year":"2011","unstructured":"Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081\u20137.","journal-title":"Urology"},{"key":"1902_CR2","doi-asserted-by":"crossref","unstructured":"Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. Linthicum: American Urological Association; 2019.","DOI":"10.1097\/JU.0000000000000309"},{"issue":"12","key":"1902_CR3","first-page":"CD003193","volume":"12","author":"BP Rai","year":"2012","unstructured":"Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12(12):CD003193.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1902_CR4","doi-asserted-by":"publisher","first-page":"e026391","DOI":"10.1136\/bmjopen-2018-026391","volume":"9","author":"SM Szabo","year":"2019","unstructured":"Szabo SM, Gooch K, Schermer C, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9(5):e026391.","journal-title":"BMJ Open"},{"issue":"1","key":"1902_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/nau.24536","volume":"40","author":"RR Dmochowski","year":"2021","unstructured":"Dmochowski RR, Thai S, Iglay K, et al. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40(1):28\u201337.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"1902_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/JU.0000000000001440","volume":"205","author":"YS Song","year":"2021","unstructured":"Song YS, Lee HY, Park JJ, Kim JH. Persistence and adherence of anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis. J Urol. 2021;205(6):1595\u2013604.","journal-title":"J Urol"},{"issue":"9","key":"1902_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"JS Benner","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276\u201382.","journal-title":"BJU Int"},{"issue":"3","key":"1902_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324\u201333.","journal-title":"Eur Urol"},{"issue":"6","key":"1902_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","volume":"32","author":"CR Chapple","year":"2014","unstructured":"Chapple CR, Nitti VW, Khullar V, et al. Onset of action of the \u03b23-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;32(6):1565\u201372.","journal-title":"World J Urol"},{"key":"1902_CR10","unstructured":"MYRBETRIQ\u00ae (mirabegron extended-release tablets). Full prescribing information. Northbrook: Astellas Pharma US, Inc.; 2018."},{"issue":"4","key":"1902_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","volume":"74","author":"C Gratzke","year":"2018","unstructured":"Gratzke C, van Maanen R, Chapple C, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase\u00a03 study (SYNERGY II). Eur Urol. 2018;74(4):501\u20139.","journal-title":"Eur Urol"},{"issue":"2","key":"1902_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316\u201324.","journal-title":"J Urol"},{"issue":"5","key":"1902_CR13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","volume":"205","author":"D Staskin","year":"2021","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase\u00a03 trial (EMPOWUR). J Urol. 2021;205(5):1421\u20139.","journal-title":"J Urol"},{"key":"1902_CR14","unstructured":"GEMTESA\u00ae (vibegron). Full Prescribing Information. Irvine; 2020."},{"key":"1902_CR15","doi-asserted-by":"crossref","unstructured":"Brucker BM, McHale K, King J, Mudd PN. Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors. Presented at Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 2021 Winter Meeting; February 25\u201327, 2021. Virtual Congress; 2021.","DOI":"10.1016\/j.curtheres.2022.100674"},{"key":"1902_CR16","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","year":"2011","unstructured":"Higgins JPT, Thomas J, Chandler J, et al editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. Chichester: Wiley; 2011."},{"issue":"449","key":"1902_CR17","first-page":"89","volume":"95","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. A nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95(449):89\u201398.","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"1902_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","volume":"120","author":"S Herschorn","year":"2017","unstructured":"Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562\u201375.","journal-title":"BJU Int"},{"issue":"7","key":"1902_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/j.1464-410X.2005.05785.x","volume":"96","author":"RR Dmochowski","year":"2005","unstructured":"Dmochowski RR, Sanders SW, Appell RA, Nitti VW, Davila GW. Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int. 2005;96(7):1049\u201354.","journal-title":"BJU Int"},{"issue":"6","key":"1902_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1902_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","volume":"63","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase\u00a03 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296\u2013305.","journal-title":"Eur Urol"},{"issue":"2","key":"1902_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","volume":"82","author":"S Herschorn","year":"2013","unstructured":"Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313\u201320.","journal-title":"Urology"},{"issue":"2","key":"1902_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase\u00a03 trial. Eur Urol. 2013;63(2):283\u201395.","journal-title":"Eur Urol"},{"issue":"4","key":"1902_CR24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388\u201395.","journal-title":"J Urol"},{"issue":"6","key":"1902_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/bju.12649","volume":"113","author":"O Yamaguchi","year":"2014","unstructured":"Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951\u201360.","journal-title":"BJU Int"},{"issue":"7","key":"1902_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/nau.22645","volume":"34","author":"HC Kuo","year":"2015","unstructured":"Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685\u201392.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1902_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.eururo.2007.03.070","volume":"52","author":"E Colli","year":"2007","unstructured":"Colli E, Parazzini F, Olivieri L, et al. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials. Eur Urol. 2007;52(2):525\u201330.","journal-title":"Eur Urol"},{"issue":"2","key":"1902_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2019-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective \u03b23-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642\u20137.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01902-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01902-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01902-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T17:11:54Z","timestamp":1673284314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01902-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1902"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01902-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,18]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}